In addition, our immunoassays revealed significant features of high-risk AML patients in terms of immune escape, especially the high expression of classical immune checkpoint molecules (e.g., PDCD1, CTLA4), which further suggests that these patients may escape from the attack of the immune system through immune checkpoint inhibition mechanisms (44–46). The gene discussed is CTLA4; the disease is acute myeloid leukemia.